ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 5-17 years of age with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

开始日期2020-07-01

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04314934

/ Completed临床2/3期

Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04575259

/ Completed临床2期

Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

100 项与 Blarcamesine 相关的临床结果

登录后查看更多信息

100 项与 Blarcamesine 相关的转化医学

登录后查看更多信息

100 项与 Blarcamesine 相关的专利（医药）

登录后查看更多信息

项与 Blarcamesine 相关的文献（医药）

2026-04-01·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Emerging neurobiological targets in psychiatric treatment

Review

作者: Berk, Michael ; Govinnage, Janani ; Giorlando, Frank ; De Zoysa, Agampodi Ishan ; Narayanaswamy, J C ; Dodd, Seetal

Despite significant advancements in psychopharmacology, there are inadequate treatment options for many psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders. This review explores emerging neurobiological targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptors, and Orexin. Recent evidence suggests that sodium channel modulators, such as evenamide, may offer therapeutic benefits for treatment-resistant schizophrenia by stabilizing glutamatergic neurotransmission. NPY-based therapies have potential in stress-related disorders, foreshadowing rapid anxiolytic and antidepressant effects through modulation of the stress response. NK1 receptor antagonists, although inconsistent in mood disorders, show promise in addiction treatment by reducing substance cravings. The P2 × 7 receptor, a key regulator of neuroinflammation, has been implicated in mood disorders, and its pharmacological inhibition may provide neuroprotective benefits. Additionally, Sigma-1 receptor agonists, including Blarcamesine and Pridopidine, have shown neuroprotective and cognitive-enhancing properties, making them attractive candidates for psychiatric and neurodegenerative disorders. Orexin receptor antagonists, such as suvorexant and seltorexant, have potential in mood disorders and substance dependence, highlighting the broader therapeutic applications of targeting the orexinergic system. While these emerging therapeutic targets hold promise, challenges remain in translating preclinical findings into effective clinical applications. Large-scale, placebo-controlled trials are necessary to establish their efficacy and safety. The identification of biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision medicine approaches. Targeted pharmacological interventions offer a path toward more effective, well-tolerated, and potentially individualized treatment options for patients with severe mental illness.

2025-12-01·Alzheimers & Dementia

Precision Medicine in Alzheimer’s Disease (AD): Observed Efficacy Treatment Effects from Blarcamesine Clinical AD Trials

Article

作者: Gueddou, Ayoub ; Courreges, Olivier ; Missling, Christopher U ; Guizard, Nicolas ; Lopez‐Talavera, Juan Carlos ; Sabbagh, Marwan N. ; Villa, Luca ; Gabelle, Audrey ; Jin, Kun ; Gordon, Elizabeth ; Chezem, William R. ; Grimmer, Timo ; Borrot, Mathilde

Abstract:

Background:

Precision Medicine represents a transformative approach in treating Alzheimer’s disease (AD), focusing on tailoring interventions based on individual genetic, molecular, clinical and environmental profiles in addition to confirm clear Mechanism of Action (MoA). This strategy aims to optimize treatment outcomes by identifying patient subgroups that are most likely to benefit or benefit at a higher degree from specific therapies, thus reducing inefficacies and potentially adverse effects associated with generalized treatment regimens.

Method:

Blarcamesine, a selective modulator of the Sigma‐1 receptor (SIGMAR1), has garnered attention due to its role in autophagy, cellular stress response, protein homeostasis, and neuroprotection. Recent clinical studies have confirmed its effects in the majority of AD patients who carry the homozygous wild‐type (WT) SIGMAR1 genotype (∼70% of the whole population) (Hampel et al., 2020).

Result:

In the Phase IIb/III ANAVEX2‐73‐AD‐004 trial, a clear MoA of oral once daily blarcamesine, a pre‐specified efficacy analysis confirmed the importance of SIGMAR1 to clinical response. While all trial participants improved significantly versus placebo after 48 Weeks, 36.3% for ADAS‐Cog13 and 27.6% for CDR‐SB, respectively, a further, also significant, improvement was observed in the prespecified analysis of SIGMAR1 carriers. Compared to the ITT group, participants carrying the SIGMAR1 WT gene observed further improvement versus placebo of 49.8% and 33.7% for the primary and secondary key endpoints ADAS‐Cog13 and CDR‐SB, respectively (Macfarlane et al., 2025).

Conclusion:

Thus, the specificity of blarcamesine to this genotype underscores the importance of understanding clear MoA and potential for further improved personalized medicine in AD treatment, as therapies targeting individual molecular profiles could achieve more substantial and sustained benefits. While Precision Medicine holds great promise for improving the treatment paradigm of AD by offering more personalized, likely more effective therapies, it also introduces challenges related to potential cost, data privacy, ethical concerns, and inequities in access. Addressing these issues is crucial to ensure that the benefits of Precision Medicine can be realized for all patients.

2025-12-01·Alzheimers & Dementia

Phase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease Patients

Article

作者: Sabbagh, Marwan N. ; Chezem, William R. ; Gabelle, Audrey ; Jin, Kun ; Macfarlane, Stephen ; Lopez‐Talavera, Juan Carlos ; Grimmer, Timo ; Missling, Christopher U

Abstract:

Background:

There are no approved oral disease‐modifying small molecule therapies for treatment of early Alzheimer’s disease (AD). Blarcamesine is an orally bioavailable small molecule that enhances autophagy through SIGMAR1 activation and restoration of cellular homeostasis in early AD.

Method:

The ATTENTION‐AD study was an up to 144‐week open‐label extension study subsequent the 48‐Week Phase IIb/III double‐blind placebo‐controlled ANAVEX ® 2‐73‐AD‐004 study, to evaluate the safety and efficacy of oral once daily blarcamesine in 508 participants with early AD. Delayed‐start analysis was performed to assess the effect of early treatment initiation up to 192 Weeks.

Result:

The ATTENTION‐AD trial confirmed the good efficacy and safety profile of once daily oral blarcamesine and also demonstrated the manageable nature of the most frequent treatment emergent adverse event (TEAE) (dizziness) observed in the preceding ANAVEX ® 2‐73‐AD‐004 trial, which was generally transient in duration (approx. 7‐11 days) and mild or moderate in severity (Grade 1 or 2). The titration schedule was adjusted to a slightly longer titration period in the ATTENTION‐AD trial, from previous 2‐3 weeks to 10 weeks. A markedly lower frequency of the TEAE of dizziness in the respective maintenance phase was observed: from previously 25.2% in the ANAVEX ® 2‐73‐AD‐004 trial to 9.6% in the ATTENTION‐AD trial, demonstrating the manageable nature of this TEAE. No severe or life‐threatening adverse events were attributed to blarcamesine. No Amyloid Related Imaging Abnormalities (ARIA) adverse events were identified. There were no deaths related to blarcamesine. Efficacy of the cognitive and functional endpoints in the delayed‐start analysis of treatment resulted in significant outcomes, ADAS‐Cog13 (LS mean difference ‐3.83, P = 0.0165) and ADCS‐ADL (LS mean difference +4.30, P = 0.0206) at Week 192, reflecting importance of early treatment initiation with oral blarcamesine.

Conclusion:

Blarcamesine significantly reduced clinical decline showing meaningful benefit for early Alzheimer’s disease patients. Blarcamesine exhibited a favorable safety profile with no treatment‐related deaths and demonstrated no associated neuroimaging adverse events with continued treatment over 4 years. Altogether, these results indicate that blarcamesine may be an effective, safe, and novel scalable oral treatment for early AD.

204

项与 Blarcamesine 相关的新闻（医药）

2026-05-29

·今日头条

不用打针了？全球首款口服阿尔茨海默靶向药正在申请上市

老张今年68岁，退休前是中学数学老师，方程式解了一辈子。去年开始，他出门买菜会忘记回家的路，炒了三十年的红烧肉突然不记得放盐还是没放盐。家里人带他去省城的三甲医院，做了PET—CT和脑脊液检测后，确诊早期阿尔茨海默病。医生告诉家属，现在有靶向药了，叫仑卡奈单抗，能延缓认知衰退27%。但紧跟着就是一盆冷水。每两周要去医院做一次静脉输注。治疗期间，需要定期MRI监测脑部是否出现水肿或出血。一年下来光药费就要18万，还不算路费、住宿费和陪护的误工费。老张家在湖南一个小县城，离最近能做这个治疗的三甲医院两百多公里。儿子在广东打工，女儿在本地带孩子，谁来每两周送老人去省城输一次液？老张一家的故事，是中国近1700万阿尔茨海默症患者家庭的缩影。而现在，一个可能改变这一切的消息传来了。一颗药丸，能不能替代一根针管 2024年底，一家名叫Anavex的美国生物制药公司，向欧洲药品管理局提交了一款名为blarcamesine的药物上市申请。这是全球第一款以口服小分子形式申请上市的阿尔茨海默病靶向药，每天只需吃一粒。这件事之所以引起全球关注，是因为它触及了阿尔茨海默治疗领域一个最痛的痛点——给药方式。目前全球已经获批上市的阿尔茨海默靶向药，无论是卫材公司的仑卡奈单抗还是礼来公司的多奈单抗，本质上都是单克隆抗体。这类药物是大分子蛋白质，口服的话会被胃酸和消化酶分解掉，根本到不了大脑。所以，只能通过静脉注射或皮下注射的方式给药。静脉输注意味着什么？意味着患者必须定期前往具备输注条件的医院，由专业医护人员操作。以仑卡奈单抗为例，标准方案是每两周输注一次，持续至少18个月。治疗期间，因为抗淀粉样蛋白抗体有一个特殊的副作用叫ARIA，全称"淀粉样蛋白相关影像异常"，可能导致脑水肿甚至脑出血，患者需要在第5次、第7次、第14次输注前做核磁共振扫描，一旦出现可疑症状还要紧急追加检查。这套流程，对于北京、上海、广州这些大城市的大型三甲医院来说，问题不大。但对于中国广袤的县域和农村地区，几乎是一道不可逾越的门槛。而口服药，只需要一杯水。不走寻常路的治病逻辑 Blarcamesine这款药物之所以值得单独拿出来说，不仅仅因为它是口服的，更因为它治病的思路和现有靶向药完全不同。仑卡奈单抗和多奈单抗的原理，是直接去清除大脑中已经堆积的β淀粉样蛋白斑块。可以理解为，大脑里积了一堆垃圾，这两款药就是派了一队清洁工去铲垃圾。 Blarcamesine走了另一条路。它激活的是一个叫Sigma—1受体的蛋白质，这个受体在神经细胞的内质网上大量存在。 Sigma—1受体被激活之后，会启动细胞内部一套叫“自噬”的清理机制。所谓自噬，就是细胞自己把内部错误折叠的蛋白质、损坏的细胞器打包送去“回收站”降解处理。换句话说，现有的抗体药物是从外面派人进去清垃圾，而blarcamesine是让细胞自己学会倒垃圾。这个区别带来了两个重要的实际好处。一是安全性上的优势。现有的抗淀粉样蛋白抗体之所以会引起ARIA，就是因为抗体和斑块结合后引发了炎症反应，导致血脑屏障通透性改变，脑组织出现水肿和出血。 Blarcamesine作为小分子药物，通过增强细胞自身的清理能力来发挥作用。临床试验中，没有发现需要常规核磁共振监测的安全信号。在一项508人参与的IIb/III期临床试验中，48周治疗后，服药组的脑萎缩速度显著低于安慰剂组。二是使用上的便捷。小分子口服药不需要冷链运输，不需要配备输注设备和专业护理人员，也不需要频繁去医院做核磁共振监测。一瓶药放在床头柜上，每天早上吃一粒，就这么简单。 1700万家庭等不起的时间要理解口服靶向药对中国的意义，需要看几个数字。根据2025年发布的《中国阿尔茨海默病报告》，截至2021年，中国阿尔茨海默病及相关痴呆患者总数达到1699万，占全球病例数的近30%。过去30年，这个数字几乎翻了四倍。再看治疗的可及性。仑卡奈单抗2024年1月在中国获批上市后，卫材公司最初预计首批能接受治疗的中国患者只有大约1500人。为什么这么少？不是没有患者，而是大多数患者根本够不到这个治疗。一方面，确诊早期阿尔茨海默病本身就需要一套复杂的检查。通过认知评估、脑部核磁共振、PET—CT或脑脊液检测，来确认淀粉样蛋白阳性，还要检测APOE基因型来评估用药风险。这一整套流程，在很多地级市医院都没法完成，更不用说县级医院。另一方面，即使确诊、满足治疗条件，每两周一次的静脉输注加上定期的核磁共振监测，对大多数普通家庭来说，经济成本和时间成本都难以承受。仑卡奈单抗一年的药费约18万人民币，尚未纳入国家医保目录。后来获批的多奈单抗虽然改为每四周输注一次，但全疗程费用依然超过36万元。一位神经内科专家曾经这样感慨过，这些新药对大城市里的中产家庭或许还有可能触及，但对于中国绝大多数的基层和农村家庭来说，这些药物从获批的那一天起就是“看得见、够不着”的存在。审批之路远比想象中坎坷故事讲到这里，必须说一个不那么美好的现实。 Blarcamesine的上市之路并不顺利。 2024年11月，Anavex向欧洲药品管理局提交了上市申请，申请获得了受理。但2025年11月，欧洲药品管理局的人用药品委员会给出了否定意见。 2025年12月，正式建议拒绝批准。 Anavex提出了重新审查的请求，但在2026年3月25日撤回了申请。为什么被拒？核心原因，在于临床试验的数据不够“漂亮”。在那项508人参与的IIb/III期试验中，blarcamesine确实在认知量表ADAS—Cog13上达到了统计学显著差异，治疗组的认知衰退速度比安慰剂组减缓了36.3%。这个数字，甚至在数值上超过了仑卡奈单抗的27%。问题出在另一个共同主要终点上：日常生活能力量表ADCS—ADL没有达到统计学显著差异。欧洲的监管机构认为，一款阿尔茨海默药不能只证明认知测试分数有改善，还必须同时证明患者的日常生活功能得到了有意义的维护。不过，Anavex并没有放弃。 2026年3月30日，也就是撤回欧洲申请后的第五天，公司发布了一份全面的监管更新，表示正在继续与欧洲药品管理局对话，推进口服blarcamesine在早期阿尔茨海默病中的开发计划。同时，公司也向美国FDA提交了补充数据，正在探索通往新药申请的可能路径。在2026年3月的AD/PD国际会议上，Anavex展示了新的数据分析，显示blarcamesine的临床效果与脑容量保留之间存在一致的相关性。用通俗的话说，吃药的患者不仅认知下降变慢了，大脑的萎缩速度也在放缓。这两件事是配套发生的，提示药物可能正在从结构层面对大脑产生保护作用。值得一提的是，后续的亚组分析发现，在不携带特定Sigma—1受体基因变异的患者中，blarcamesine的效果更加明显。这意味着未来这款药如果获批，有可能通过基因检测来筛选出最适合的患者群体，走精准医疗的路线。口服药的大门，不只这一扇即便blarcamesine的审批之路还要再走一段时间，它已经证明了一件重要的事情：口服小分子药物治疗阿尔茨海默病，在科学上是行得通的。这扇门一旦被推开，后面跟进的不会只有一家公司。事实上，阿尔茨海默领域的药物研发正在出现一个明确的趋势转变。过去二十年，几乎所有的资源都押注在抗淀粉样蛋白的单克隆抗体上。这条路虽然终于走通了，但抗体药物天然的局限性摆在那里。需要注射、价格高昂、副作用需要密切监测，这些特点使得它很难成为一种普及型的治疗手段。越来越多的研究团队开始探索其他靶点和其他给药方式。除了blarcamesine瞄准的Sigma—1受体和自噬通路，还有针对神经炎症、tau蛋白磷酸化、突触功能等多个方向的口服候选药物正在不同阶段的临床试验中推进。对于中国来说，口服药的意义远远超出了“方便”两个字。它意味着，治疗有可能从大城市的三甲医院，延伸到县级医院甚至社区卫生服务中心。它意味着，一个普通退休工人家庭不需要倾家荡产也能用上靶向治疗。 Blarcamesine的故事，还没有结束。它在欧洲碰了壁，但科学数据并没有被否定。认知量表上36.3%的改善是真实的，脑萎缩的减缓是真实的，Sigma—1受体激活自噬通路清除错误蛋白质的机制也在反复被独立实验验证。监管机构的谨慎是对患者的保护，而不是对科学的否定。也许两年后，也许三年后，第一款口服阿尔茨海默靶向药终将摆上药架。到那一天，一位县城退休教师的女儿走进社区药房，花一个普通家庭能够承受的价格，就能够买到一盒药带回家，倒一杯温水递给父亲。这个画面，值得所有人一起期待。

2026-05-25

·李乐教授

看完《给阿嬷的情书》，聊聊阿尔茨海默症的治疗进展

昨天看完了《给阿嬷的情书》，最后谢南枝得了阿尔茨海默症，已经不记得太多以前的事情了，但是最后还记得给木生一家邮寄腌猪肉，那一段把我看哭了。看到阿尔茨海默症，正好对这个病的用药有一点研究，就想着聊两句吧。阿尔茨海默症简称AD，俗称老年痴呆，是一种缓慢进展的神经退行性疾病。患者逐渐失去记忆，最后连身边的人都不认识了。过去几十年里，医务工作者没有太好的办法根除疾病的影响，只能一点一点看着疾病发展，多奈哌齐和美金刚算是有一些效果的上市药物，但是也无法阻止疾病的发展，像撒切尔夫人这样的外国领导人，得了这个病也是没有太多办法的。时间到了2023年，美国FDA批准了一个新药治疗阿尔茨海默症，叫做仑卡奈单抗（Lecanemab，商品名Leqembi），随后多奈单抗也获批上市，这两个药物直接作用疾病的可能发病机制，大脑中异常沉淀的β-淀粉样蛋白（Aβ）。我们可以把这个蛋白理解成大脑里的垃圾，健康大脑会及时清理这些蛋白，但是得了阿尔茨海默症，这些蛋白会逐渐聚集，最终形成板块，破坏大脑细胞，影响认知。这两个药物属于单克隆抗体，可以作用于这些斑块或者形成斑块的中间状态，临床试验显示他们让患者的认知下降速度明显减缓。 2026年礼来公司还推进了下一代药物remternetug的3期临床试验，这个药物可以像胰岛素一样在家里自己注射，不用经常去医院静脉输液。除了皮下注射，药物研发专家也在努力研究口服抗阿尔茨海默症的药物。目前有一个口服药还是比较有希望的，叫做blarcamesine，正在临床试验。罗氏公司开发了的一个叫做trontinemab的药物，这个药采用了罗氏独有的脑穿梭技术，听起来很酷，可以解决药物穿透血脑屏障的难题。2025年下半年已经进入了三期临床阶段，如果成功，意义非凡。除了抗体药物，还有小核酸药物疗法，主要针对的是tau蛋白，这个也是阿尔茨海默症的另外一个病理标志，目前Arrowhead公司研发的一款药物预计在26年下半年公布临床数据。如果成功，同样意义非凡。好消息说完了，下面说说坏消息。新药也是有一些风险的，极少数情况下可能引发癫痫或者其他。另外这些药物主要用于早期轻度患者，中重度患者，并没有明显获益。所以阿尔茨海默症治疗的关键原则是，越早干预效果越好。我国在25年年底将仑卡奈单抗纳入首批商业保险创新药目录，让不少家庭减轻了负担。未来，单一药物可能无法攻克这个疾病，科学家在探索治疗艾滋病一样采用鸡尾酒疗法，多个药物协同。还有一些非药物治疗，也证明对于延缓认知衰退有一定的帮助。虽然电影的结局无法改变，但是医学正在改写这个疾病的结局，今天，我们第一次拥有了干预疾病进展的武器，它虽不能治愈，但足以让患者多几个月甚至几年的独立生活能力。如果你或家人出现了记忆力明显减退、语言表达困难等早期症状，请及时到神经内科或记忆门诊就诊。行舟入夜，恰江上升明月，似与你并肩重归。病程万里，药在身旁，便不觉无望。

2026-05-22

·anavex.com

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

About UsTeam Careers ConditionsAlzheimer’s Disease Parkinson’s Disease Schizophrenia Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Pain Rett Syndrome Stroke Therapeutic CandidatesBlarcamesine (ANAVEX® 2-73) ANAVEX® 3-71 ANAVEX® 1-41 ANAVEX® 1066 PatientsSIGMACEPTOR InvestorsInvestor Resources Events Analyst Coverage Corporate Governance Share Data News Team Careers Alzheimer’s Disease Parkinson’s Disease Schizophrenia Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Pain Rett Syndrome Stroke Blarcamesine (ANAVEX® 2-73) ANAVEX® 3-71 ANAVEX® 1-41 ANAVEX® 1066 SIGMACEPTOR Investor Resources Events Analyst Coverage Corporate Governance Share Data About UsTeam Careers ConditionsAlzheimer’s Disease Parkinson’s Disease Schizophrenia Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Pain Rett Syndrome Stroke Therapeutic CandidatesBlarcamesine (ANAVEX® 2-73) ANAVEX® 3-71 ANAVEX® 1-41 ANAVEX® 1066 PatientsSIGMACEPTOR InvestorsInvestor Resources Events Analyst Coverage Corporate Governance Share Data News Team Careers Alzheimer’s Disease Parkinson’s Disease Schizophrenia Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Pain Rett Syndrome Stroke Blarcamesine (ANAVEX® 2-73) ANAVEX® 3-71 ANAVEX® 1-41 ANAVEX® 1066 SIGMACEPTOR Investor Resources Events Analyst Coverage Corporate Governance Share Data About UsTeam Careers ConditionsAlzheimer’s Disease Parkinson’s Disease Schizophrenia Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Pain Rett Syndrome Stroke Therapeutic CandidatesBlarcamesine (ANAVEX® 2-73) ANAVEX® 3-71 ANAVEX® 1-41 ANAVEX® 1066 PatientsSIGMACEPTOR InvestorsInvestor Resources Events Analyst Coverage Corporate Governance Share Data News Team Careers Alzheimer’s Disease Parkinson’s Disease Schizophrenia Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Pain Rett Syndrome Stroke Blarcamesine (ANAVEX® 2-73) ANAVEX® 3-71 ANAVEX® 1-41 ANAVEX® 1066 SIGMACEPTOR Investor Resources Events Analyst Coverage Corporate Governance Share Data About UsTeam Careers ConditionsAlzheimer’s Disease Parkinson’s Disease Schizophrenia Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Pain Rett Syndrome Stroke Therapeutic CandidatesBlarcamesine (ANAVEX® 2-73) ANAVEX® 3-71 ANAVEX® 1-41 ANAVEX® 1066 PatientsSIGMACEPTOR InvestorsInvestor Resources Events Analyst Coverage Corporate Governance Share Data News Team Careers Alzheimer’s Disease Parkinson’s Disease Schizophrenia Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Pain Rett Syndrome Stroke Blarcamesine (ANAVEX® 2-73) ANAVEX® 3-71 ANAVEX® 1-41 ANAVEX® 1066 SIGMACEPTOR Investor Resources Events Analyst Coverage Corporate Governance Share Data NEW YORK, NY, May 22, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company’s inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026. As indicated in the Notice, the Company has until July 20, 2026, to submit a plan to regain compliance. The Company is working prudently to complete and file the Form 10-Q and submit a plan to regain compliance with the Nasdaq Listing Rule. This notification has no immediate effect on the Company’s common stock listed on Nasdaq. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s plans to complete and file its Form 10-Q and to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s ability to file the Form 10-Q and the Company’s ability to regain compliance with Nasdaq Listing Rule 5250(c)(1) and other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent filings and furnishings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law. Investor Relations & Media Contact: SCR Partners, LLC Alex Arzeno Tel: 203-550-3972 Email: alex@scr-ir.com Tripp Sullivan Tel: 615-942-7077 Email: tsullivan@scr-ir.com Company Contact: Sandra Boenisch Principal Financial Officer Anavex Life Sciences Corp. Tel: 1-844-689-3939 Email: ir@anavexcorp.com Anavex is dedicated to advancing brain health by developing innovative oral medicines designed to improve patients lives. Alzheimer’s Disease Parkinson’s Disease Schizophrenia Rett Syndrome Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Alzheimer’s Disease Parkinson’s Disease Schizophrenia Rett Syndrome Angelman Syndrome Depression Fragile X Syndrome Frontotemporal Dementia Infantile Spasms Corporate Presentation Therapeutic Candidates Investor Resources Share Data Events Careers Our Values A Letter from the CEO Corporate Presentation Therapeutic Candidates Investor Resources Share Data Events Careers Our Values A Letter from the CEO Receive updates directly to your inbox on company announcements, clinical progress, and regulatory developments. Forward Looking Statement Code of Conduct Legal Notice Privacy Policy Contact Forward Looking Statement Code of Conduct Legal Notice Privacy Policy Contact

100 项与 Blarcamesine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11383	Blarcamesine	-	DB05592

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	申请上市	欧盟	Anavex Life Sciences Corp.	2023-11-20
认知功能障碍	申请上市	欧盟	Anavex Germany GmbH	2023-11-20
Rett综合征	临床3期	澳大利亚	Anavex Life Sciences Corp.	2019-05-06
Rett综合征	临床3期	英国	Anavex Life Sciences Corp.	2019-05-06
脆性X综合征	临床3期	美国	Anavex Life Sciences Corp.	-
帕金森病所致痴呆	临床2期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病所致痴呆	临床2期	西班牙	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床2期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床2期	西班牙	Anavex Life Sciences Corp.	2018-07-09
天使综合征	临床1期	-	Anavex Life Sciences Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine (the early-start treatment groups)	範築淵壓窪觸製鹹觸範(艱鬱窪願遞窪構憲鹽淵): Difference (LS Mean) = -3.83, P-Value = 0.0165 更多	积极	2025-07-31
				Blarcamesine (the late-start treatment groups)
NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	blarcamesine (early start treatment)	艱廠網範鹹餘夢襯憲鬱(願鏇範構願鹹鬱遞築願) = from previously 25.2% in the ANAVEX®2-73-AD-004 trial to 9.6% in the ATTENTION-AD trial. 淵簾餘願窪鑰餘選願鹽 (繭窪夢餘夢衊餘艱製範 ) 更多	积极	2025-01-13
				blarcamesine (late start treatment)
NCT04314934 (GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine 50 mg	窪繭鏇齋憲蓋餘獵積鏇(製鏇蓋獵糧繭襯鏇醖鬱) = 鏇鹹餘廠觸淵齋獵窪鹹壓築積糧願齋遞艱製製 (築窪鬱鹹膚艱積鏇憲願 ) 更多	积极	2024-07-28
				Blarcamesine 30 mg	窪繭鏇齋憲蓋餘獵積鏇(製鏇蓋獵糧繭襯鏇醖鬱) = 繭鏇鏇憲糧鏇夢構鬱憲壓築積糧願齋遞艱製製 (築窪鬱鹹膚艱積鏇憲願 ) 更多
NCT04304482 (EXCELLENCE, GlobeNewswire) 人工标引	临床2/3期	Rett综合征	92	ANAVEX2-73	醖鑰繭壓積淵醖遞網鹽(遞糧醖餘願觸淵憲廠鑰) = 廠鏇淵獵淵鹹製構齋願網餘鹽鹽齋壓選築蓋憲 (窪鹽遞窪齋鑰鹹製鹹壓, 2.150) 更多	积极	2024-01-02
				Placebo	醖鑰繭壓積淵醖遞網鹽(遞糧醖餘願觸淵憲廠鑰) = 繭製網膚壓糧淵艱選艱網餘鹽鹽齋壓選築蓋憲 (窪鹽遞窪齋鑰鹹製鹹壓, 2.537) 更多
NCT03790709 (Corporate Publications) 人工标引	临床2/3期	阿尔茨海默症	508	ANAVEX2-73	壓齋構壓選襯觸選壓鹹(膚夢糧壓選餘齋繭願鑰): Difference = -1.783 (95% CI, −3.314 ~ −0.251), P-Value = 0.0226 达到更多	积极	2023-09-14
				Placebo
NCT03790709 (ANAVEX2-73-AD-004, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	509	Blarcamesine	鏇衊憲願構網齋糧壓壓(壓鹹製遞鏇範廠網範觸): OR = 1.84, P-Value = 0.015 更多	积极	2022-12-01
				Placebo
NCT03758924 (Biospace) 人工标引	临床2期	Rett综合征 SIGMAR1	-	Blarcamesine	構齋積醖構積積鹹憲觸(鏇糧構選選鑰網衊醖選) = 製餘構鏇淵夢構網鏇窪憲觸膚鏇鑰獵襯淵獵鬱 (範顧築衊餘鬱願淵艱壓 ) 更多	积极	2021-06-21
				Placebo	-
CTAD2015	临床2期	-	-	ANAVEX 2-73	膚鏇繭獵顧鏇積積夢築(網鬱憲範壓鬱製願鬱膚) = The average Cogstate test improved across the test batteries 築構願遞鹽範夢夢憲鏇 (鹹襯憲廠鹽餘廠壓簾蓋 ) 更多	积极	2015-11-04